Ciwon Lafiya

Shan magungunan rage radadin jiki kafin a yi allurar rigakafin COVID-19 ko bayan an yi na tattare da hadari – Binciken DUBAWA

Zargi – Wani sakon da ake yadawa a manhajan sakonni na WhatsApp na zargin cewa shan magungunan rage radadin jiki irin su Diclofenac bayan an yi allurar rigakafin COVID-19 na da lahani kuma zai iya kai ga mutuwa.

Tun bullowar allurar rigakafin COVID-19 ake samun takadama iri-iri dangane da sahihancin allurar. Takaddamar ta danganci inganci, da karfin aiki da kuma farashin sayen allurar.

Ba da dadewan nan ba aka sami wani sakon da ake yadawa a manhajan sakonni na WhatsApp wanda ke cewa shan magunguna irinsu Diclofenac (maganin da ake yawan amfani da shi wajen rage radadin jiki, kumburin jiki da ciwo ko radadin gabobin kashi) da saura makamantan su bayan karbar allurar rigakafin COVID-19 na iya kasancewa da hadarin gaske har ma zai iya kai ga mutuwa.

Wannan zargi ya samo asali ne daga mutuwar wata likita mai suna Dr Hari Harini wadda ake kyautata zaton ta rasu ne bayan da maigindata, wanda shi ma likita ne, ya yi mata allurar Diclofenac bayan ta karbi allurar rigakafin COVID-19. Wannan labarin ne aka rika yadawa sau da yawa a WhatsApp tare da hoton marigayiyar da maigidanta.

Labarai masu alaka da allurar rigakafin COVID-19 sun dauki hankali sosai a baya-bayan nan. Domin irin sarkakiya da hadarin da batun yake da shi ga lafiya da ma rayuwar mutane, ba abu ne da ya kamata a yi wasa da shi ba. Dan haka ne DUBAWA ta dauki nauyin tantance wannan bayani.

Tantancewa

Dangane da batun mutuwar likitar, na farko dai DUBAWA ta gano bayanai da dama dangane da abun da ya janyo mutuwar likitar sai dai maganin rage radadin jiki ko ciwo bai kasance daya cikin abubuwan da ake hasashe sun janyo mutuwar ba.

A cewar wani binciken da kafar yada labaran Thenewsminute ta Indiya ta yi, likitoci sun ce allurar COVID-19 ba ita ce sanadiyyar mutuwar Dr. Harini a asibitin Madurai ranar 11 ga watan Maris ba. Shugaban asibitin ‘yan mishan na Meenakshi a Madurai, Dr Kannan, ya fadawa kafar labaran The News Minute cewa ranar 5 ga watan Fabrairu aka yi mata allurar rigakafin, wato wata guda kafin aka kawo ta asibitin cikin mawuyacin halin da ma bata cikin haiyacinta. Ita ma kafar yada labaran The quint ta bayyana hakan.

Sai dai duk da haka, dangane da batun cewa magungunan rage radadin jiki na da hadari bayan an karbi allurar COVID-19, akwai dokokin da Hukumar Yaki da Bazuwar Cututtuka ta CDC ta gindaya wajen amfani da alluran da aka amince a baiwa jama’a a Amurka. Daya daga ciki shi ne bai kamata mutun ya sha maganin rage radadin jiki kafin karbar rigakafin a matsayin wani mataki na kaucewa lahanin da ka iya biyo bayan allurar ba.

A yi magana da likita kan shan magunguna irinsu Ibuprofen da acetaminophen, da aspirin, ko antihistamines dan radadi ko wani rashin jin dadin jikin da ka iya zuwa bayan an yi rigakafi.

Mutum zai iya amfani da wadannan magungunan ne kadai idan har likita ya tabbatar cewa babu wata cuta ko lahanin da zai hana shi yin hakan.

Wani binciken da wata kasidar nazarin kwayoyin cuta ta wallafa dangane da tasirin magungunan rage radadin bayan karbar rigakafin COVID-19 ya gano cewa shan magungunan da ke rage kumburin jiki irinsu Ibuprofen na rage karfin garkuwar jiki da ma sassan garkuwan jikin da ke yaki da kwayar cutar da ke janyo COVID-19 wadda aka fi sani da SARS-CoV-2

Tunda garkuwar jiki ne ke samar da kwayoyin rigakafin da ke iya yaki da kwayoyin cuta irinsu SARS-CoV-2, binciken na ganin cewa batun na iya kasasncewa gaskiya. Tunda allurar rigakafin da ake bayarwa tana inganta garkuwar jiki ne ta yadda za ta samar da kwayoyin rigakafin da za su kai hari kan coronavirus ba tare da janyo cuta ba. Shi ya sa marubutan wannan binciken suka ce wannan na nuna yiwuwar cewa magungunan rage radadin na iya hana garkuwar jikin mutun aiki yadda ya kamata, inda har za su iya rage karfin aikin allurar a jikin dan adam.

Haka nan kuma Dr Sherrill Brown, darektan sashen da ke tabbatar da kariya daga kamuwa da cututtuka a AltaMed Health Services, wata cibiyar kiwon lafiya ta tarayya da ke gundumomin Los Angeles da Orange a jihar Carlifornia, ta amince da sakamakon wannan bincike inda ta kara da cewa “Shawarata ita ce mutun ya jira har sai ya ga alamu kamar zazzabi, ko irin radadin da ke bukatar magunguna, ba wai mutun ya sha magungunan a matsayin kariya tun kafin ya sami alamun wani lahani ba.”

Dr Brown ta kuma bayyana cewa “Wasu mutane ba za su iya shan acetaminophen ko ibuprofen ba saboda suna da cututtukan da suka hana su yin haka. Abun da ya fi dacewa da irin wadannan mutanen shi ne su tuntubi jami’an lafiya ko likitocin da aka amince da su kafin su sha irin wadannan magungunan. Idan ba za ka iya shan magungunan rage radadi bayan karbar allurar rigakafin coronavirus ba, ko kuma kana so ka guji shan magungunan akwai wadansu hanyoyin samun sauki na daban. Misali idan kana so ka rage zafi a wajen da aka yi allurar a hannu, kana iya sa tsumma mai sanyi a kan wajen ka dan matsa dan rage kumburi. Kana kuma iya motsa hannun ta yadda zai inganta yawon jini. Wannan ma zai iya rage ciwo.

Unduibisi Okeke wani masanin harhada magungana a asibitin Limi da ke Abuja, ya yi bayani makamancin na Dr Brown. Ya bayyanawa DUBAWA cewa “allurar rigakafin COVID-19 bako ne a jikin dan dam. Dan haka zafi ko radadin da akan ji duk daga yunkurin da jiki yake yi ne ya karbi allurar rigakafin dan ta saje da sauran jikin.” Ya kuma kara da cewa “Idan aka cigaba da jin radadi a jiki mutun na iya shan diclofenac da sauransu. Sai dai tunda allurar sabuwa ce kuma ana cigaba da gudanar da bincike, ya dace a guji kowani irin magani bayan allurar har sai an gama tantance duk abubuwan da suka shafi allurar rigakafin ta corornavirus”

A Karshe

Bincike na nuna cewa shan magungunan rage radadin jiki bayan an yi allurar rigakafin COVID-19 na iya kasancewa babban hadari musamman idan ba’a tambayi shawarar likita ba. Duk da cewa mutuwar Dr. Harini ba ta da alaka da COVID-19, kwararru na ba da shawarar cewa a guji shan magungunan da aka ambata idan har za’a karba ko bayan an karbi allurar rigakafin COVID-19


Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button